Discover CME, tools, and guideline-focused education to improve your knowledge - and patient outcomes.
KRAS G12C Biology: Why Is This Mutation Different?
Timothy F. Burns, MD, PhD
Safety Considerations and AE Monitoring for Trial Participation With Combination Regimens
From Biopsy to Results: Building a Reflex-Ready Testing Workflow
Gerard A. Silvestri MD, MS
Navigating the Evidence: Emerging Frontline Combination Strategies in KRAS G12C NSCLC
From Disease Assessment to Advanced Therapy: A Practical Framework for Atopic Dermatitis
Kristine Kucera, PA-C, MPAS, DHSc
Translating Safety Data Into Practice: Effective AE Management in Oral SERD and PROTAC Regimens
Virginia Kaklamani, MD, DSc
Redefining Endocrine Therapy: The Evidence Behind Oral SERDs and PROTAC ER Degraders
Komal Jhaveri, MD, FACP
Case Consult: Implementing Anti-CD38–Based Frontline Regimens in Transplant-Ineligible Patients
Saad Z. Usmani, MD, MBA
Natalie S. Callander, MD
Closing the Gap in First-Line Treatment of KRAS G12C–Mutated Advanced NSCLC: From Biology to Bedside Decisions and Trial-Ready Care
Getting Trial-Ready: Matching Patients to Frontline Studies of KRAS G12C Inhibitors
SOHO 2026 Debrief: Translating the Latest CLL Data Into Community Practice Decisions
Jennifer R. Brown, MD, PhD
Navigating Treatment Selection After First-line CDK4/6 Inhibitor Progression
Oral SERDs and PROTACs in ER+/HER2− mBC: Testing Smarter, Treating Better
Case Consult: Implementing Anti-CD38–Based Frontline Regimens in Transplant-Eligible Patients
Clinical Evidence for Anti-CD38–Based Frontline Regimens in Transplant-Ineligible Patients With Multiple Myeloma
The Frontline Imperative: Integrating Anti-CD38–Based Regimens Into Multiple Myeloma Care in Community Practice
Menin Inhibitors in AML: Six Clinical Showdowns That Shape Real-World Practice
Amer Zeidan, MBBS
Ghayas Issa, MD
Case Consult: PD-L1–Guided Treatment Decisions in Platinum-Resistant Ovarian Cancer
Kathleen N. Moore, MD
Ritu Salani, MD
Case Consult: Treatment Strategies for HER2-Positive Platinum-Resistant Ovarian Cancer
Treatment Decisions That Matter: A Case-Based Discussion in Advanced Ovarian Cancer
Clinical Evidence for Anti-CD38–Based Frontline Regimens in Transplant-Eligible Patients With Multiple Myeloma
Case Consult: Personalizing First-Line Maintenance Therapy in Advanced Ovarian Cancer
Case Consult: Treatment Strategies for FRα-Positive Platinum-Resistant Ovarian Cancer
The CELMoD Shift: Translating Protein Degradation Science Into Practice-Changing Myeloma Care
December 11, 2026 New Orleans, Louisiana
On the Horizon: Emerging Antigen-Directed Strategies Across Disease Stage
Ticiana Leal, MD
Beyond Checkpoint Blockade in SCLC: Emerging Antigen Targets and Treatment Strategies Across Disease Stages
Neal Ready, MD, PhD
Loading...
We're glad to see you're enjoying Prova Education… but how about a more personalized experience?
Press cancel to remain on Prova Education. Press the link below or the continue button to keep going.